Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IMMUNOPEC nivolumab plus MesoPher around CRS-HIPEC for peritoneal mesothelioma
NL-OMON60110Phase 2Recruiting
- Sponsor
- Erasmus MC
- Start
- May 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Dendritic Cell Vaccines → Immune Effector Cells → Other Cell Types → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label trial of nivolumab and MesoPher in peritoneal mesothelioma, sponsored by Erasmus MC. Primary endpoint: Progression-free survival. Started May 2026; status: recruiting.
02
Drugs
nivolumabMesoPher
03
Conditions
peritoneal mesothelioma
Beyond the preview
Go deeper on NL-OMON60110.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60110.